BCR-ABL1 mutation ≠ ponatinib resistance

被引：4
|
作者：
Saglio, Giuseppe [1 ]
Fava, Carmen [1 ]
机构：
[1] Univ Turin, I-10124 Turin, Italy
来源：
BLOOD | 2016年 / 127卷 / 06期
关键词：
CHRONIC MYELOID-LEUKEMIA; CHROMOSOME-POSITIVE LEUKEMIAS; INHIBITOR; AP24534; POTENT;
D O I：
10.1182/blood-2015-12-685149
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：666 / +
页数：2
相关论文
共 50 条
  • [1] Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib
    Singh Anand, Anand Prakash
    Umbarkar Prachi, Prachi
    Tousif, Sultan
    Lal, Hind
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2020, 316 : 214 - 221
  • [2] Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients
    Deininger, Michael W.
    Hodgson, J. Graeme
    Shah, Neil P.
    Cortes, Jorge E.
    Kim, Dong-Wook
    Nicolini, Franck E.
    Talpaz, Moshe
    Baccarani, Michele
    Mueller, Martin C.
    Li, Jin
    Parker, Wendy T.
    Lustgarten, Stephanie
    Clackson, Tim
    Haluska, Frank G.
    Guilhot, Francois
    Kantarjian, Hagop M.
    Soverini, Simona
    Hochhaus, Andreas
    Hughes, Timothy P.
    Rivera, Victor M.
    Branford, Susan
    BLOOD, 2016, 127 (06) : 703 - 712
  • [3] The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib
    Parker, Wendy T.
    Yeung, David T. O.
    Yeoman, Alexandra L.
    Altamura, Haley K.
    Jamison, Bronte A.
    Field, Chani R.
    Hodgson, J. Graeme
    Lustgarten, Stephanie
    Rivera, Victor M.
    Hughes, Timothy P.
    Branford, Susan
    BLOOD, 2016, 127 (15) : 1870 - 1880
  • [4] Declaration of Bcr-Abl1 independence
    Zhao, Helong
    Deininger, Michael W.
    LEUKEMIA, 2020, 34 (11) : 2827 - 2836
  • [5] Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib
    Latifi, Yllka
    Moccetti, Federico
    Wu, Melinda
    Xie, Aris
    Packwood, William
    Qi, Yue
    Ozawa, Koya
    Shentu, Weihui
    Brown, Eran
    Shirai, Toshiaki
    McCarty, Owen J.
    Ruggeri, Zaverio
    Moslehi, Javid
    Chen, Junmei
    Druker, Brian J.
    Lopez, Jose A.
    Lindner, Jonathan R.
    BLOOD, 2019, 133 (14) : 1597 - 1606
  • [6] The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model
    Pouwer, Marianne G.
    Pieterman, Elsbet J.
    Verschuren, Lars
    Caspers, Martien P. M.
    Kluft, Cornelis
    Garcia, Ricardo A.
    Aman, Jurjan
    Jukema, J. Wouter
    Princen, Hans M. G.
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2018, 5
  • [7] Migrating to Long-Read Sequencing for Clinical Routine BCR-ABL1 TKI Resistance Mutation Screening
    Schaal, Wesley
    Ameur, Adam
    Olsson-Stromberg, Ulla
    Hermanson, Monica
    Cavelier, Lucia
    Spjuth, Ola
    CANCER INFORMATICS, 2022, 21
  • [8] Migrating to Long-Read Sequencing for Clinical Routine BCR-ABL1 TKI Resistance Mutation Screening
    Schaal, Wesley
    Ameur, Adam
    Olsson-Stromberg, Ulla
    Hermanson, Monica
    Cavelier, Lucia
    Spjuth, Ola
    CANCER INFORMATICS, 2022, 21
  • [9] CML - Not only BCR-ABL1 matters
    Rinke, Jenny
    Hochhaus, Andreas
    Ernst, Thomas
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2020, 33 (03)
  • [10] No Benefit of BCR-ABL1 Screening in Polycythemia
    Langabeer, Stephen E.
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2016, 10 (07) : EL5 - EL5
12345